Luan Tao, Hao Jianqing, Gu Yingying, He Ping, Li Yijia, Wang Liqiang, Deng Haiyi, Guan Wenhui, Lin Xinqing, Xie Xiaohong, Deng Yu, Wang Shuaiying, Wang Changchun, Li Jingxu, Li Ru, Luan Yang, Yang Gang, Zhang Yunhui, Zhong Nanshan, Zhou Chengzhi
Faculty of Life science and Technology, Kunming University of Science and Technology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, 650500, China.
National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510000, China.
BMC Cancer. 2024 Dec 31;24(1):1597. doi: 10.1186/s12885-024-13277-4.
The aim of this study is to explore the clinicopathological features, radiographic manifestations, treatment options, and prognosis of primary pulmonary angiosarcoma (PPAS).
We summarized and analyzed the clinical data of 11 patients with primary pulmonary angiosarcoma treated at the First Affiliated Hospital of Guangzhou Medical University between January 2018 and January 2024. A retrospective analysis was conducted in conjunction with a review of the relevant literature.
Among the 11 cases, the primary symptoms were nonspecific respiratory issues, with chest pain, cough, and shortness of breath being the most common. Initial diagnosis was correct in only 2 cases, while the remaining 9 cases were misdiagnosed as other conditions, such as lung nodules, infections, or pulmonary embolism. All patients were ultimately diagnosed via pathology, with CD31 and CD34 showing a high positivity rate of 60%. Of the 11 patients, 9 have died, and 2 remain alive. The average survival period was 13.2 months.Based on the number of lesions, PPAS was categorized into three types: solitary, multiple, and invasive pulmonary artery. The average survival period for the solitary type (2 cases) was 15.5 months, for the multiple type (5 cases) was 6.6 months, and for the pulmonary artery type (4 cases) was 20.5 months. Among the 3 patients who underwent surgery, the median overall survival (OS) was 23.0 months, whereas for the 8 non-surgical patients, the median OS was 9.7 months.
Primary pulmonary angiosarcoma is a rare, highly aggressive vascular malignancy characterized by nonspecific clinical symptoms and a tendency for metastasis and pulmonary artery embolism. Currently, no effective treatment exists, and the overall prognosis is poor.
本研究旨在探讨原发性肺血管肉瘤(PPAS)的临床病理特征、影像学表现、治疗方案及预后。
我们总结并分析了2018年1月至2024年1月在广州医科大学附属第一医院接受治疗的11例原发性肺血管肉瘤患者的临床资料。结合相关文献进行回顾性分析。
11例患者中,主要症状为非特异性呼吸问题,胸痛、咳嗽和气短最为常见。仅2例初始诊断正确,其余9例被误诊为其他疾病,如肺结节、感染或肺栓塞。所有患者最终均通过病理确诊,CD31和CD34显示出60%的高阳性率。11例患者中,9例死亡,2例存活。平均生存期为13.2个月。根据病变数量,PPAS分为三种类型:孤立型、多发型和侵犯肺动脉型。孤立型(2例)的平均生存期为15.5个月,多发型(5例)为6.6个月,肺动脉型(4例)为20.5个月。3例接受手术的患者中,中位总生存期(OS)为23.0个月,而8例非手术患者的中位OS为9.7个月。
原发性肺血管肉瘤是一种罕见的、高度侵袭性的血管恶性肿瘤,具有非特异性临床症状,且有转移和肺动脉栓塞倾向。目前尚无有效治疗方法,总体预后较差。